Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1996-10-21
1999-08-17
Higel, Floyd D.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
424401, 424433, 514397, C07D23302, C07D23304, C07D23354, A61K 31415
Patent
active
059395559
DESCRIPTION:
BRIEF SUMMARY
The present invention relates to novel Polymorphs B and C of azole mononitrate-compound known as sertaconazole mononitrate (WHO).
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is an infrared (IR) spectrum of sertaconazole mononitrate Polymorph B.
FIG. 2 is a differential scanning calorimetry (DSC) thermogram of sertaconazole mononitrate Polymorph B.
FIG. 3 is an X-ray powder diffractogram of sertaconazole mononitrate Polymorph B.
FIG. 4 is an infrared (IR) spectrum of sertaconazole mononitrate Polymorph C.
FIG. 5 is a differential scanning calorimetry (DSC) thermogram of sertaconazole mononitrate of Polymorph C.
FIG. 6 is an X-ray powder diffractogram of sertaconazole mononitrate Polymorph C.
FIG. 7 is an infrared (IR) spectrum of sertaconazole mononitrate Polymorph A.
FIG. 8 is a differential scanning calorimetry (DSC) of sertaconazole mononitrate Polymorph A.
FIG. 9 is an X-ray diffractogram of sertaconazole mononitrate Polymorph A.
DETAILED DESCRIPTION OF THE INVENTION
zole mononitrate is used in therapeutics as an antifungal agent. The preparation of this compound was disclosed in European Patent No. 0151477. The applicants have found out that sertaconazole mononitrate exhibits two novel polymorphs, B and C, which have a melting point in the range of 163-164.degree. C. and 164.5-165.5.degree. C. respectively. The present invention provides a process for obtaining selectively each polymorph B and C of sertaconazole mononitrate. In the aforesaid patent, sertaconazole mononitrate, which will be hereinafter referred as Polymorph A, was obtained with a melting point of 156-157.degree. C. The applicants have found out in the course of different crystallization assays that when polymorph A is recrystallized from absolute ethanol, it yields the new polymorph B, and when polymorph A is recrystallized from chloroform, it yields the new polymorph C. The melting points of the three polymorphs are within a close range, but they are well differentiated by means of the enclosed IR spectra, DSC thermograms and X-ray powder diffractograms. FIGS. 7, 8 and 9 concerning Polymorph A are enclosed in order to support the differences between the new polymorphs B or C and primary polymorph A.
The physical properties of polymorphs B and C of sertaconazole mononitrate are different from those of primary polymorph A. In effect, polymorph B shows higher stability than that of polymorph A versus a moderate supply of external energy (such as sifting and homogenizing processes) and is, therefore, suitable for the preparation of topical dosage solid forms, such as a powder. Polymorph C is assumed to be even more stable than polymorph B versus an external energetic supply and can, therefore, be conveniently used in processes requiring a higher energetic supply, such as compression processes, thus being suitable for the preparation of tablets. In case of liquid formulations, either polymolph, B or C, can be used since the proper characteristics of a solid disappear in a solution.
In addition to the aforesaid pharmaceutical forms, polymorphs B and C of sertaconazole mononitrate mixed with pharmaceutically acceptable carriers can be administered by the oral route to humans and animals in the form of capsules, syrups, solutions, powder, etc., by an injectable route, by a rectal route, and by a vaginal-intrauterine route in the form of ovulum, ointment, cream, pessary, lotion, etc., at daily doses ranging from 100 to 800 mg; and by a topical route in the form of a cream, lotion, ointment, emulsion, solution, shampoo, gel, etc., at concentrations ranging from 0.1 to 5%.
Also polymorphs B and C of sertaconazole mononitrate in admixture with a diluent or carrier and in suspension with irrigation water can be used against crop diseases; they can also be applied by atomizing, spraying, dusting, or in the form of cream, paste, etc., at the rate of 0.1-15 kg per hectare of soil.
The following examples will illustrate the preparation of polymorphs B and C of sertaconazole mononitrate, and pharmaceutical formulations containing them. The examples a
REFERENCES:
patent: 5135943 (1992-08-01), Foguet et al.
Arneimittel-Forschung Drug Research, vol. 42, No. 5A, 1992 DE, pp. 695-698 Albet et al.
Pharmaceutical Anal., vol. 117, 1992, p. 449.
Anglada Lluis
Castello Josep Maria
Foguet Rafael
Ortiz José A.
Raga Manuel Mauricio
Ferrer Internacional S.A.
Higel Floyd D.
LandOfFree
Polymorphs B and C of idazole mononitrate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polymorphs B and C of idazole mononitrate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphs B and C of idazole mononitrate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-315935